Menu
  • Publish Your Research/Review Articles in our High Quality Journal for just USD $99*+Taxes( *T&C Apply)

Research Article

Efficiency Evaluation of Commercially Veterinary Rabies Vaccine after the Primary Immunization against Fatality

Boonyakorn Wongsakul*, Nattawadee Monon, Chanon Fangoen and Chonlatip Pipattanaboon

Corresponding Author: Boonyakorn Wongsakul, Department of Animal Diagnosis and Investigation, Queen Saovabha Memorial Institute, The Thai Red Cross Society, 1871 Rama 4 Road, Pathum Wan, Bangkok 10330, Thailand.

Received: June 06, 2023 ;    Revised: June 09, 2023 ;    Accepted: June 12, 2023 ;   Available Online: June 22, 2023

Citation: Wongsakul B, Monon N, Fangoen C & Pipattanaboon C. (2023) Efficiency Evaluation of Commercially Veterinary Rabies Vaccine after the Primary Immunization against Fatality. J Vet Marine Res, 3(1): 1-7.

Copyrights: ©2023 Wongsakul B, Monon N, Fangoen C & Pipattanaboon C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Share Your Publication :

Views & Citations

2707

Likes & Shares

0


Global Views

  • Abstract
  • Full Text
  • Images
  • Tables
  • References
  • PDF
  • Supplementary Files

The Rabies Virus (RBV) is a contagious zoonotic disease with no known treatment, but it can be prevented through immunization in both humans and animals. The key to successful rabies vaccination lies in the availability of high-quality vaccines capable of eliciting an immune response that reaches the adequate protective level set at 0.5 IU/ml by the World Health Organization (WHO). Furthermore, the vaccination should effectively prevent the occurrence of fatalities in vaccinated animals. Two commercially available rabies vaccines from Thailand were assessed in Syrian Hamsters to determine the Rabies Neutralization Antibody (RVNA) levels post-vaccination and to observe the survival rate. Both vaccines were found to induce immune responses that exceeded the protective threshold of 0.5 IU/ml at one month and the first three months after vaccination (P-value = 0.00 and 0.11, respectively, for Vaccine A, and 0.00 and 0.11, respectively, for Vaccine B). At the sixth month after vaccination, both groups of Syrian hamsters exhibited a Geometric Mean Titer (GMT) of RVNA at the levels of 0.378 IU/ml for Vaccine A and 0.096 IU/ml for Vaccine B, resulting in a 90% survival rate. The surviving animals demonstrated a range of Nab levels between 0.003-1.06 IU/ml. This indicates that an immune level of 0.5 IU/ml alone may not provide sufficient protection against infection. However, a threshold of 0.5 IU/ml should still be considered when establishing rabies-free areas.

Mpgyi